The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.

CVS Health reported strong Q2 2026 results with adjusted EPS of $2.58 (up 42.5% YoY) and revenues of $106.10 billion (up 7.3%), beating consensus estimates. The company raised full-year 2026 guidance for earnings and revenues. However, estimates have trended downward over the past month with a -6.08% consensus shift, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.

The global eClinical Solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a CAGR of 13.98%. Growth is driven by increased demand for efficient clinical trials, rising chronic disease prevalence, adoption of AI and cloud computing technologies, and decentralized trial models. Key players include Oracle, Veeva Systems, IQVIA, Medidata Solutions, and IBM Watson Health.

The global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. Strategic consolidation continues with major acquisitions strengthening end-to-end capabilities.

Moore Law PLLC is investigating ICON plc (NASDAQ: ICLC) following the company's announcement of an internal audit committee investigation into accounting practices and controls initiated in October 2025. ICON's stock price dropped significantly on February 12, 2026, when the company disclosed the investigation and delayed its earnings release to April 30, 2026.

Icon Public (ICLR), a clinical research organization, surged nearly 11% on Wednesday after delivering first-quarter 2026 results that beat analyst expectations. While revenue grew modestly by 0.9% to $2 billion and net income fell 27%, the company's gross bookings jumped 22% year-over-year to $3.3 billion, signaling strong demand for its services in the biotech and pharmaceutical sectors.

The global decentralized clinical trials market is projected to grow from USD 9.9 billion in 2025 to USD 38.3 billion by 2035, at a CAGR of 14.5%. Growth is driven by digital health technologies, remote patient engagement, and ecosystem expansion involving CROs and platform vendors. Oncology represents the largest therapeutic segment at 45% market share, while pharmaceutical and biotech sponsors lead end-user adoption at 55% market share. North America currently dominates, while Asia-Pacific shows the fastest growth.

The clinical trial data visualization market is projected to grow from $0.89 billion in 2025 to $1.82 billion by 2030 at a CAGR of 15.4%, driven by increasing adoption of AI-powered solutions, cloud-based platforms, and decentralized trials. Major players include ICON plc, Oracle Corporation, and IQVIA Inc., with Asia-Pacific emerging as the fastest-growing region.

The eCOA, eSource, and clinical trials market is projected to grow from $51.15 billion in 2025 to $81.46 billion by 2030 at a 9.8% CAGR, driven by AI adoption, decentralized trial models, and digital transformation. Key growth factors include regulatory acceptance of electronic records, cloud-based systems, and real-time data capture. Despite tariff challenges, regional software development is strengthening market resilience.

ICON Public Limited Company's Audit Committee is investigating accounting practices and internal controls related to revenue recognition from fiscal years 2023-2025. The company disclosed material weaknesses in internal controls, delayed financial results, and withdrew 2025 guidance. ICON shares fell approximately 40% on the announcement, declining from $133.14 to $80.08 per share on February 12, 2026.

The FDA granted Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for treating advanced, HPV-unrelated head and neck squamous cell carcinoma in adults. The drug is being evaluated in combination with Merck's Keytruda in an ongoing Phase 3 trial. Additionally, J&J extended its contract with Trellus Health for patient support services through mid-2026.

The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.